Delivery Order SPE2DB20D3103-SPE2DB23FN7C6
- Not listed
- This federal contract award, valued at $2,782.09, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4,561,182,545 units of Naloxone HCL 4 mg Nasal Spray, a critical medication used to treat opioid overdoses. This is a firm fixed-price delivery order with a completion date of June 9, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a...
- This federal contract award, valued at $3,571.71, was issued by the Medical Supply Chain division of the U.S. Defense Logistics Agency (DLA) to the Corporate Office division of Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4,564,641,340 units of Naloxone HCl 4 mg nasal spray, a critical medication used to treat opioid overdose. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 with the DLA Troop...
- This federal contract award, valued at $2,397.78, was granted by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4,563,143,368 units of Naloxone HCL 4 mg Nasal Spray, with a completion date of December 20, 2023. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., which holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999.00. This...
- This federal contract award, valued at $1,199.86, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4,562,071,512 units of Naloxone HCl 4 mg Nasal Spray, a critical medication used for the treatment of opioid overdose. The contract has a completion date of September 7, 2023 and is a firm fixed-price delivery order. There was no set-aside designation for this award, indicating full and open...
- This federal contract award, valued at $1,838.72, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,567,999,320 units of Naloxone HCl 4 mg Nasal Spray, a critical medication used to treat opioid overdoses. This delivery order contract has a firm fixed-price pricing type and an ultimate completion date of April 23, 2025. Amerisourcebergen Drug Corp also...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,560,983,291 units of Naloxone HCL 4 mg Nasal Spray. The delivery order, valued at $1,845.84, has a firm fixed-price and is expected to be completed by May 19, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company, Cencora, Inc., which holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- This federal contract award, valued at $7,194.83, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for 4,557,108,798 units of 4 mg Naloxone HCL nasal spray, a medication used to treat opioid overdose. The contract has a completion date of May 5, 2022 and utilizes a firm fixed price pricing type. Amerisourcebergen Drug Corp is a subsidiary of the parent company...
- This federal contract award, valued at $9,121.93, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 4,556,709,275 units of Naloxone HCl 4 mg Nasal Spray, a critical medication used to treat opioid overdoses. This contract is not designated as a set-aside and was awarded through open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $1,356.24 firm-fixed-price delivery order is for the supply of 4,562,019,962 units of Naloxone HCL 4 mg Nasal Spray. The contract has a completion date of September 1, 2023 and was awarded on August 31, 2023. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- This federal contract award, valued at $14,421.35, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of Naloxone Hydrochloride 4 mg Nasal Spray, a critical medication used to reverse opioid overdoses. This is a delivery order contract with a firm fixed price type and an ultimate completion date of May 15, 2023. The contract does not have a set-aside designation, indicating open competition....
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB23FN7C6Delivery Order
This federal contract award, valued at $2,321.64, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4,561,244,594 units of Naloxone HCl 4 mg Nasal Spray, a critical medication used for the emergency treatment of opioid overdose. This contract does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000, for similar medical products and prescription drugs. These IDCs enable the efficient procurement of essential pharmaceutical and medical supplies to serve the healthcare needs of military personnel, veterans, and other federal beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 6/14/23 |